Leqvio Drug Interactions with Statins, Ezetimib & More

Inclisiran is the generic name; Leqvio is the brand name (Novartis). It is a small interfering RNA (siRNA) conjugated to N-acetylgalactosamine (GalNAc), classified as a PCSK9-directed RNA interference therapy, a distinct mechanism from the monoclonal antibody PCSK9 inhibitors evolocumab (Repatha) and alirocumab (Praluent), and unrelated to GLP-1 receptor agonists despite occasional confusion in general searches. Inclisiran is FDA-approved as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering.

Inclisiran (Leqvio, a GalNAc-conjugated siRNA PCSK9-directed therapy) has no pharmacokinetic drug interaction identified in its FDA-approved label, because it is not a cytochrome P450 substrate, inhibitor, or inducer and does not act on major efflux or uptake transporters such as P-glycoprotein, OATP1B1/1B3, or BCRP. This applies to the approved 284 mg subcutaneous dosing schedule (Day 1, Day 90, then every six months) in adults with HeFH or established ASCVD. Its combinations with statins, ezetimibe, and bempedoic acid are pharmacodynamic, additive LDL-C lowering rather than a metabolic interaction, and the label does not require dose adjustment for any of these pairings. Readers should confirm the current label language at the time of use, since prescribing information can be updated after the 2021 approval reviewed here.

What Established Evidence Says, and What Is Still Unproven

Established (from the FDA-approved label): Inclisiran is not metabolized by CYP450 enzymes, is cleared by nuclease-mediated degradation into nucleotide fragments excreted renally, and is not a substrate or inhibitor of the transporters most responsible for classic drug-drug interactions. Plasma concentrations fall to near-undetectable levels within about 48 hours of each injection, well before the drug's six-month pharmacodynamic effect on PCSK9 has worn off, because the durable effect happens inside hepatocytes rather than in circulating plasma.

Plausible but not formally studied: Combinations with newer lipid agents such as bempedoic acid have a clean mechanistic rationale for lacking interaction, but a dedicated interaction study specific to inclisiran plus bempedoic acid was not identified in the material available for this review. The same caveat applies to co-administration timing with other subcutaneous injectables (GLP-1 agonists, insulin, PCSK9 antibodies) at the same clinic visit, there is no pharmacokinetic reason for concern, but no formal same-visit study was located either.

Not established: Exact trial-level percentages for LDL-C reduction, patient counts, and p-values attributed in earlier drafts of this topic to specific NEJM publications could not be verified against a confirmed primary source in this review and should not be treated as sourced numbers until an editor checks the original ORION-10 and ORION-11 publications directly. This article uses the FDA label's general efficacy language ("approximately 50% LDL-C reduction") rather than repeating unverified trial statistics.

How Inclisiran Works, and Why That Shapes Its Interaction Profile

Inclisiran silences the gene that produces PCSK9 inside liver cells. Lower PCSK9 protein means LDL receptors stay active on the hepatocyte surface longer, pulling more LDL-C out of circulation. After subcutaneous injection, the GalNAc conjugate directs the siRNA almost exclusively to hepatocytes via the asialoglycoprotein receptor; once inside the cell, the antisense strand loads into the RNA-induced silencing complex (RISC) and cleaves PCSK9 messenger RNA before it can be translated.

This is the mechanistic reason inclisiran's interaction profile looks different from most small-molecule drugs: the drug itself barely persists in the bloodstream, so it is not available to compete for metabolic enzymes or transporters the way an oral small molecule would be. Per the FDA label, plasma levels fall to near-undetectable within about 48 hours of injection, while the PCSK9-lowering effect inside the liver lasts roughly six months.

Why There Are No Confirmed Pharmacokinetic Interactions

No CYP450 involvement

The FDA-approved prescribing information states that inclisiran is not metabolized by cytochrome P450 enzymes and does not inhibit or induce any CYP isoform. It is broken down by nucleases into nucleotide fragments excreted in urine. Based on this, drugs cleared through CYP3A4 (clarithromycin, tacrolimus, many statins' minor pathway), CYP2C9 (warfarin), or other CYP isoforms are not expected to have altered exposure when inclisiran is added.

No transporter involvement

The label describes in vitro data indicating inclisiran is not a substrate, inhibitor, or inducer of P-glycoprotein, BCRP, OATP1B1, OATP1B3, or the OAT/OCT renal transporters. This matters because several commonly co-prescribed drugs (atorvastatin and rosuvastatin via OATP1B1/BCRP, digoxin via P-gp, metformin via OCT1/OCT2) depend on these transporters for their own pharmacokinetics, and inclisiran does not compete with them.

Confirm the current FDA prescribing information for Leqvio before relying on any specific transporter or enzyme claim, since labels can be amended after approval.

Pharmacodynamic Interactions: Additive LDL-C Lowering, Not a Metabolic Conflict

Absence of a pharmacokinetic interaction does not mean absence of any clinically relevant interaction. Several lipid-lowering drugs are commonly combined with inclisiran deliberately, because reducing cholesterol synthesis through a separate pathway tends to raise PCSK9 expression as a compensatory response, which is part of why adding a PCSK9-directed therapy to a statin produces a bigger LDL-C drop than either alone.

Statins. Statins reduce intracellular cholesterol synthesis, which tends to up-regulate hepatic PCSK9 expression. Combining a statin with inclisiran is the standard clinical scenario reflected in the approved indication (inclisiran is studied and labeled as an add-on to maximally tolerated statin therapy). No statin dose adjustment is indicated for this combination based on inclisiran's mechanism.

Ezetimibe. Ezetimibe blocks intestinal cholesterol absorption via NPC1L1 and modestly raises hepatic PCSK9 expression, similar in direction to statins. The combination is used clinically without a pharmacokinetic interaction concern; the expected effect is additive LDL-C lowering.

Bempedoic acid. Bempedoic acid inhibits ATP-citrate lyase upstream of HMG-CoA reductase. There is a plausible mechanistic case for additive, non-interacting LDL-C lowering with inclisiran, but a dedicated bempedoic acid plus inclisiran interaction trial was not confirmed for this review, treat any specific percentage for this combination as unverified until checked against a primary source.

Bile acid sequestrants. Cholestyramine, colesevelam, and colestipol act only in the gut lumen and are not systemically absorbed. Because inclisiran is injected subcutaneously and never passes through the GI tract, no interaction of any kind is expected.

Clinical guidelines from cardiology societies support adding a PCSK9-targeted therapy for very-high-risk ASCVD patients who remain above LDL-C goals on maximally tolerated statin plus ezetimibe. The exact wording of any specific guideline statement, and whether it names inclisiran directly versus PCSK9 antibodies as a class, should be checked against the current published guideline text rather than assumed from summary language.

Anticoagulants and Antiplatelets

Patients who need inclisiran for ASCVD are frequently on anticoagulant or antiplatelet therapy.

Warfarin. Warfarin is metabolized mainly through CYP2C9 and CYP3A4. Since inclisiran does not act on either enzyme, there is no pharmacokinetic mechanism by which starting or stopping inclisiran would move INR. Confirm with the treating clinician that any INR changes are being attributed to warfarin's usual sources of variability (diet, other new medications, illness), not to inclisiran.

Direct oral anticoagulants (DOACs). Apixaban, rivaroxaban, edoxaban, and dabigatran depend on P-glycoprotein and, for some agents, CYP3A4. Inclisiran has no activity at either site, so no DOAC dose adjustment is indicated based on inclisiran co-administration.

Antiplatelets. Aspirin, clopidogrel, ticagrelor, and prasugrel do not share a metabolic pathway with inclisiran. Ticagrelor is a CYP3A4 substrate, but because inclisiran does not modulate CYP3A4, ticagrelor exposure is not expected to change.

Diabetes Medications

Type 2 diabetes and ASCVD frequently coexist, and many inclisiran patients are also on glucose-lowering therapy.

GLP-1 receptor agonists. Semaglutide, liraglutide, dulaglutide, and tirzepatide are peptides cleared by proteolytic degradation rather than CYP enzymes, so no pharmacokinetic interaction with inclisiran is expected. Some GLP-1 agonists have a modest independent LDL-lowering effect associated with weight loss; the size of that effect and its relevance when stacked with inclisiran needs verification against a primary trial source rather than being quoted as a fixed percentage.

SGLT2 inhibitors. Empagliflozin, dapagliflozin, and canagliflozin are cleared primarily through UGT glucuronidation and renal excretion. Inclisiran has no activity at UGT enzymes, so no interaction is expected.

Metformin. Metformin is excreted unchanged via renal OCT1/OCT2 transporters. The FDA label indicates inclisiran does not inhibit OCT2, so no interaction risk is expected for this combination.

Immunosuppressants: The Real Interaction Sits With the Statin, Not Inclisiran

Patients on cyclosporine, tacrolimus, or sirolimus (for example, post-transplant patients with dyslipidemia) raise a legitimate interaction question, but the relevant interaction in this group is generally between the immunosuppressant and a co-prescribed statin, not inclisiran.

Cyclosporine strongly inhibits OATP1B1, OATP1B3, and P-glycoprotein. Statins that depend on these transporters (rosuvastatin, atorvastatin, simvastatin) can reach markedly higher plasma concentrations when combined with cyclosporine, raising myopathy risk. Inclisiran is neither a substrate nor an inhibitor of these transporters, so cyclosporine is not expected to change inclisiran exposure, and inclisiran is not expected to change cyclosporine levels. The statin-cyclosporine pairing should still be managed carefully by the prescribing team; inclisiran does not add to or subtract from that specific risk.

Tacrolimus and sirolimus are CYP3A4 and P-gp substrates with narrow therapeutic windows. Because inclisiran does not act on either pathway, these immunosuppressants are not expected to be affected by inclisiran co-administration.

Strong CYP Inducers (Rifampin, Phenytoin, Carbamazepine)

These agents up-regulate CYP3A4, CYP2C9, and P-glycoprotein, and can meaningfully lower plasma concentrations of many CYP-dependent drugs. Because inclisiran's activity does not depend on any of these pathways, a patient starting one of these inducers for an unrelated condition (for example, carbamazepine for epilepsy) would not be expected to need an inclisiran dose adjustment.

Renal and Hepatic Impairment Change the Risk Picture for Other Drugs, Not Inclisiran Itself

Renal impairment. Per the FDA label, mild-to-moderate renal impairment does not meaningfully change inclisiran pharmacokinetics. Severe renal impairment is associated with a reported increase in inclisiran exposure (AUC), and the label does not mandate a dose adjustment based on that finding, but any co-prescribed renally cleared drug (metformin, renally eliminated DOACs, digoxin) should still be monitored according to that drug's own label requirements, independent of inclisiran.

Hepatic impairment. Inclisiran acts inside the liver, so hepatic function is relevant to its mechanism even though it is not metabolized by CYP450. Mild hepatic impairment (Child-Pugh A) does not appear to meaningfully change inclisiran pharmacokinetics per the label. Data for moderate and severe hepatic impairment are limited, and the label advises caution. Drugs that are hepatically cleared and already sensitive to liver disease (warfarin, most statins) still require their own independent monitoring in these patients.

Special Populations

Pregnancy and lactation. Inclisiran is contraindicated in pregnancy per the FDA label, based on embryo-fetal toxicity observed in animal reproduction studies at exposures above the clinical dose. Effective contraception is advised during treatment. No human lactation data are described in the label.

Pediatric patients. Inclisiran is not FDA-approved for patients under 18 as of the 2021 label reviewed here; confirm current approval status, since pediatric indications can change.

Elderly patients. The label does not describe a clinically meaningful age-related change in inclisiran exposure. Because inclisiran does not add CYP or transporter-based interaction burden, the polypharmacy common in older adults does not, by itself, increase inclisiran-specific interaction risk, though it still increases the number of other drug pairs that need independent review.

Injection-Site and Same-Visit Considerations

Inclisiran is given as a 284 mg subcutaneous injection administered by a healthcare provider, unlike self-injected PCSK9 antibodies. There is no formal guidance located for this review on whether inclisiran should be given at the same visit as other injectables (GLP-1 agonists, insulin, PCSK9 antibodies). There is no pharmacokinetic reason for concern, since these agents act through unrelated receptors and clearance pathways, but rotating injection sites and documenting each injection separately remains reasonable practice pending explicit guidance.

Combining inclisiran with a PCSK9 monoclonal antibody (evolocumab or alirocumab) is not supported by clinical data identified for this review. Both target the PCSK9 pathway through different mechanisms, the combination has not been shown to add meaningful efficacy, and it adds cost and injection burden without an established benefit.

Decision Framework: When a "No Interaction" Answer Still Needs a Second Look

Most inclisiran interaction questions resolve to "no pharmacokinetic interaction, and the pharmacodynamic overlap is beneficial." This framework flags the specific situations where that default answer needs qualification before a clinician or patient acts on it.

The pattern across every row: inclisiran itself rarely is the variable that changes the answer. The variable that changes the answer is almost always the other drug's own clearance pathway, the patient's organ function, or whether a quoted number has been checked against a current primary source.

Monitoring

A fasting lipid panel some weeks after starting or adjusting any LDL-C-lowering therapy is standard practice for tracking response; for inclisiran, the second loading dose at Day 90 and the six-month mark are the natural checkpoints reflected in its dosing schedule. Routine liver function test monitoring is not mandated by the label specifically for inclisiran, though patients on a co-prescribed statin should continue that statin's own monitoring requirements. Renal function should be monitored per the standard nephrology approach for the patient's overall condition; inclisiran is not described in the label as worsening renal function.